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Short term Leydig cell stimulation by LH and hCG in a man with central hypogonadism 
Background: The comparison between human chorionic gonadotropin (hCG) and luteinizing 
hormone (LH) has been performed in in vitro models. Despite their action being mediated by the 
same receptor and leading to a similar increase of testosterone (T) production, it is now clear that 
LH and hCG activate differently signal transduction. However, hCG administration remains the 
therapeutic option of choice to increase intratesticular T. A direct in vivo comparison between LH 
and hCG was not performed systematically so far in the male. Here, we report the first case in 
which the short-term action of LH and hCG was on compared in the same man. Methods: A 55-
years-old patient presented with hypogonadotropic hypogonadism (HH) probably due to an atypical 
giant pituitary adenoma. HH was present both at the diagnosis and after trans-sphenoidal neuro-
surgery with complete removal of adenoma. Assuming that the long-standing HH could have 
reduced the Leydig cells responsiveness, three different schemes were consecutively administered: 
i) hCG (Gonasi HP, IBSA pharmaceutics) 75 IU daily i.m. for 2 weeks; ii) recombinant LH (rh-LH) 
(Luveris, Merck) 75 IU daily i.m. for 2 weeks; iii) hCG again 75 IU daily i.m. for 2 weeks. Each 
stimulation scheme was followed by 2-weeks of wash-out. Serum total T levels were measured by 
liquid chromatography-tandem mass spectrometry. All three treatments led to a significant increase 
in serum total T levels compared to baseline (p=0.004, p=0.010 and p=0.004, respectively), which 
occured immediately after the first injection. Although the maximal T increase reached after hCG 
administration seemed higher compared to rh-LH (3.46 vs 2.49 ng/mL), no significant differences 
were found (p=0.245). LH serum levels increased after LH administration from 2.7 to 5.7 mIU/ml, 
suggesting that a minimal, apulsatile LH increase was able to stimulate Leydig cells. Conclusion: 
This case report demonstrates, for the first time, that a daily injection of the same low dosage of 
either LH or hCG increases serum T levels in vivo, quickly reaching a steady state. Although hCG 
is expected to be more potent than LH by in vitro studies, both treatments equally increased serum 
T levels. Thus, a similar potency of LH and hCG on T production is supposed. Whether LH and 
hCG differently stimulate other Leydig celle functions (e.g. INSL3 production) remains to be 
determined. HH could represent the best in vivo model at comparing LH and hCG action and 
kinetics in the male. 
